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Musashi1 (Msi1) is a highly conserved RNA-binding
protein that is required during the development of
the nervous system. Msi1 has been characterized as a
stem cell marker, controlling the balance between
self-renewal and differentiation, and has also been
implicated in tumorigenesis, being highly expressed
in multiple tumor types. We analyzed Msi1 expres-
sion in a large cohort of medulloblastoma samples
and found that Msi1 is highly expressed in tumor
tissue compared with normal cerebellum. Notably,
1762high Msi1 expression levels proved to be a sign of
poor prognosis. Msi1 expression was determined to
be particularly high in molecular subgroups 3 and 4
of medulloblastoma. We determined that Msi1 is re-
quired for tumorigenesis because inhibition of Msi1 ex-
pression by small-interfering RNAs reduced the growth
of Daoy medulloblastoma cells in xenografts. To char-
acterize the participation of Msi1 in medulloblastoma,
we conducted different high-throughput analyses. Ribo-
nucleoprotein immunoprecipitation followed by mi-
croarray analysis (RIP-chip) was used to identify mRNA
species preferentially associated with Msi1 protein in
Daoy cells. We also used cluster analysis to identify
genes with similar or opposite expression patterns to
Msi1 in our medulloblastoma cohort. A network
study identified RAC1, CTGF, SDCBP, SRC, PRL, and
SHC1 as major nodes of an Msi1-associated net-
work. Our results suggest that Msi1 functions as a
regulator of multiple processes in medulloblastoma
formation and could become an important thera-
peutic target. (Am J Pathol 2012, 181:1762–1772; http://dx.
doi.org/10.1016/j.ajpath.2012.07.031)
RNA-binding proteins (RBPs) play a key role in gene
regulation by modulating processes such as splicing,
mRNA transport and stability, and translation. The human
genome contains approximately 800 RBPs, many of
which regulate specific groups of transcripts.1 Some
RBPs control mRNA subsets whose proteins are impli-
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proliferation, apoptosis, and differentiation.2 If the func-
tion or expression level of such RBPs is altered, the
expression of multiple genes is affected, triggering or
contributing to tumor formation.3 An important example of
such an RBP is Musashi1 (Msi1), a highly conserved
protein with functions in nervous system development,
stem cell self-renewal, and differentiation.4,5 Musashi
was originally identified in Drosophila, where it controls
asymmetric cell division in sensory precursor cells.6 In
mammals, Msi1 is considered to define a population of
multipotent stem cells in the brain,7 crypt cells in the
intestines,8 breast,9 and hair follicles.10 In the brain, Msi1
is expressed in the subventricular zone where stem cells
are located.11,12
Msi1 can function either as a negative or positive reg-
ulator of translation by binding to specific motifs located
in the 3= untranslated regions (UTRs) of its target
mRNAs.4,5 Four well-characterized mRNA targets of
Msi1 are known in mammals: Numb,13 CDKN1A,14
doublecortin,15 and Robo3.16 Numb inhibits the ex-
pression of Notch and Hedgehog and acts to prevent
degradation of the tumor suppressor p53.17 CDKN1A is
an inhibitor of cyclin-dependent protein kinases that reg-
ulate the transition through the G1/S phase of the cell
cycle18 and chromosome segregation and mitosis.19
Doublecortin is a microtubule-binding protein involved in
neural stem cell migration that is expressed in neuronal
precursor cells.15 Robo3 is a receptor involved in axonal
guidance. Robo proteins direct the growing axons to the
appropriate location and enable the crossing of the mid-
line.20 Additional targets for Msi1 have been identified by
RIP-chip analysis, which pertain to the cell cycle, apop-
tosis, proliferation, and differentiation.21
Expression of Msi1 was first observed in glioblastoma
and medulloblastoma and has since been found in sev-
eral cancers, such as hepatocellular carcinoma, cervical
cancer, lung cancer, retinoblastoma, and breast, blad-
der, endometrial, and colon cancer.22–32 Msi1 is partic-
ularly well characterized in breast and colon cancers.
Approximately 40% of primary breast tumors and 100%
of lymph node metastasis express increased levels of
Msi1, which has been correlated to a poor prognosis.29
Reduced expression of Msi1 affected the growth of cells
as spheroids and tumor xenografts.33 In the colon, Msi1
localizes within the crypt cells of the small intestine along
with stem and progenitor cells.34,35 Intestinal adenomas
of mice harboring an APC gene mutation are thought to
have increased levels of Msi1 due to a constitutively
active Wnt pathway.36–38 Colorectal tumor cells co-ex-
pressing CD133 and Msi1 are resistant to oxiliplatin and
5-fluorouracil.39 The crypts of the intestines after expo-
sure to toxic levels of 5-fluorouracil continued to express
Msi1, suggesting that Msi1-positive cells are drug resis-
tant.40 Knockdown of Msi1 by RNA interference inhibited
colon tumor cell growth as xenografts, whereas its ecto-
pic expression in intestinal epithelium progenitor cells
increased proliferation and tumorigenic capacity through
the activation of Wnt and Notch pathways.30,41
In brain tumors, high Msi1 expression is correlated with
poor prognosis in the cases of gliomas, astrocytomas,and medulloblastoma.23 In a previous study from our
laboratory, we demonstrated that increased Msi1 expres-
sion is partially caused by loss or decreased expression
of tumor suppressor microRNAs and via HuR, which in-
creases mRNA stability and translation.42,43 In gliomas,
Msi1 is associated with Notch1 expression in areas of
tumor proliferation and infiltration.23 Moreover, in an ex-
pression correlation study performed with The Cancer
Genome Atlas glioblastoma data set, we identified
Notch3 and Notch4 among the genes with the highest
correlative expression with Msi1.44 In medulloblastoma, a
connection between Msi1 and Notch pathway activation
was demonstrated by suppression subtractive hybridiza-
tion.45 Moreover, knockdown of Msi1 in Daoy medullo-
blastoma cells down-regulated the expression of Notch
pathway members, Hes1, Hey2, and Notch2.46 Msi1 in-
fluences the Notch pathway by inhibiting its repressor,
Numb.13 Knockdown of Msi1 in medulloblastoma cells
affected their proliferation and growth as spheroids, sug-
gesting a possible involvement with the so-called cancer
stem cell population.46
In this article, we report that Msi1 is a marker of poor
prognosis in medulloblastoma. Msi1 seems to control
tumor growth via a complex network of cancer-related
genes. Altogether, our data demonstrate that Msi1 is a
major player in medulloblastoma and may represent an
important therapeutic target.
Materials and Methods
Cell Culture
The Daoy human medulloblastoma cell line and human
embryonic kidney 293 (HEK293T) cells were obtained
from ATCC (Manassas, VA). Cells were cultured using
Dulbecco’s modified Eagle medium (Hyclone, Logan,
UT) supplemented with 10% fetal bovine serum (Atlanta
Biologicals, Lawrenceville, GA) and penicillin and strep-
tomycin (Gibco, Gaithersburg, MD) and incubated at
37°C in a humidified atmosphere of 5% carbon dioxide.
Tissue Arrays and Immunohistochemistry
Hematoxylin-eosin–stained sections from 259 paraffin
blocks were prepared to define representative tumor re-
gions. In addition, 10 samples of nontumor cerebellar
tissues were included as a control. All tissue specimens
were arrayed into a recipient block as previously de-
scribed.47 Evaluation of MSI1 (Abnova, Walnut, CA) im-
munostaining was performed in a semiquantitative man-
ner (positive versus negative), and cases with clear
evidence of cytoplasmic and/or nuclear staining were
considered immunopositive by two investigators (A.K.
and M.R.), who were blinded to clinical and molecular
variables.
Xenografts
Xenograft models were established by using 5-week-old,
male, athymic, nude mice. The mice were maintained
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environment. To establish tumors, 5  107 Daoy cells
were injected into the right and left flanks. Tumor size was
measured by caliper, and volume was calculated as
(length  width2)  0.5. After 15 days, groups of five
mice received three different treatments: Msi1 small-in-
terfering (siRNA) injection, control siRNA injection, and
nontreated control. siRNA was injected into the tumors
every third day for a total of 5 doses. Msi1 siRNA (se-
quence targeting the coding region of Msi1; 5=-GGC-
UUUUGGAUUUGUGCAUdTdT-3=, where the lower
case indicates deoxyribonucleotides) and a control
siRNA were obtained from Ambion (Austin, TX). Efficacy
of knockdown of Msi1 by siRNA was analyzed by real-
time PCR and Western blot (see Supplemental Figure S1
at http://ajp.amjpathol.org). The siRNAs were mixed with
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) (Avanti
Polar Lipids, Alabaster, AL) in the presence of excess
t-butanol at a ratio of 1:10 (wt/wt) (siRNA/DOPC). Tween
20 (Sigma-Aldrich, St. Louis, MO) was added to the mix-
ture in a ratio of 1:19 (Tween 20:siRNA/DOPC) and vor-
texed. The mixture was frozen in an acetone/dry ice bath
and lyophilized. The siRNA preparation was reconstituted
in 0.9% sterile saline before injecting at a dose of 5
mol/L. At the end of treatment, animals were euthanized
and the tumors removed and weighed. Size and weight
between experiment and control tumors were compared
using a paired two-tailed Student’s t-test. P 0.05 was
considered statistically significant. All values are ex-
pressed as mean  SEM.
Immunohistochemistry of Xenografts
Tumors removed from xenografts were embedded in par-
affin and cut into 4-m sections and transferred to slides.
The samples were deparaffinized, treated with a citrate
buffer, and rehydrated in graded alcohol. Staining was
completed by first blocking with avidin/biotin for 20 min-
utes and subsequent incubation with the appropriate an-
tibody overnight at 4°C. Anti-Msi1 (Abcam, Cambridge,
MA) and anti-Notch1 (Santa Cruz Biotechnology, Santa
Cruz, CA) antibodies were used for immunohistochemis-
try. A secondary antibody conjugated to horseradish per-
oxidase was added to the slides, incubated for 30 min-
utes, and then developed with 3,3=-diaminobenzidine
(Sigma-Aldrich). We used hematoxylin as a counterstain.
Slides were dehydrated in graded alcohol (dH2O-95%),
rinsed with xylene, and permanently mounted with Cryo-
seal Mounting Media 60 (Richard-Allen, Kalamazoo, MI).
RIP-Chip Experiments
RIP-chip was performed as previously described.48 Daoy
cells were grown to 100% confluency in 150-mm dishes
and then washed twice with ice-cold phosphate-buffered
saline. Lysates were prepared with 1.5 volumes of poly-
somal lysis buffer [100 mmol/L KC, 25 mmol/L EDTA, 5
mmol/L MgCl2, 10 mmol/L HEPES, pH 7.0, 0.5% Nonidet
P-40, 10% glycerol, 2 mmol/L dithiothreitol, 0.4 mmol/L
vanadyl ribonucleoside complex, one tablet of complete
protease inhibitor (Roche Applied Sciences, Indianapo-lis, IN), and RNaseOUT (Invitrogen, Carlsbad, CA)] and
centrifuged, and the supernatant was removed and
stored at 80°C. Protein A sepharose beads (GE Health-
care, Piscataway, NJ) were incubated overnight at 4°C
with either anti-Msi1 polyclonal antibody or the preim-
mune serum.46 The beads coated with antibody were
resuspended in NT2 buffer supplemented with RNase-
OUT, 0.2% vanadyl ribonucleoside complex, 2 mmol/L
dithiothreitol, and 25 mmol/L EDTA. The cell lysate was
added, and the mixture of beads and lysate was incu-
bated at room temperature while tumbling end over end.
After incubation, the beads were spun down and washed
four times with ice-cold NT2 buffer. Subsequently, the
material was digested with proteinase K, extracted with
phenol/chloroform, and precipitated with isopropanol.
RNA quality was analyzed by using an Agilent 2100 Bio-
analyzer (Agilent Technologies, Santa Clara, CA) accord-
ing to the manufacturer protocol.
Two hundred nanograms of RNA from each sample
was labeled with Cy3 or Cy5 dye using an Agilent Low
RNA Input Linear Amplification Kit (Agilent Technologies)
according to manufacturer protocol. Dye-swap was per-
formed on each sample to avoid dye-specific biases.
After amplification, 750 ng of Cy3- and Cy5-labeled RNA
were combined and hybridized to an Agilent Human
Gene expression array (Agilent Technologies). After in-
cubation, hybridized slides were washed according to
manufacturer protocol. Microarray slides were then
scanned on an Agilent Microarray Scanner G2565BA
(Agilent Technologies), and data were extracted with
Agilent Feature Extraction software version 9.1 (Agilent
Technologies).
RIP-Chip Data Analysis
All analyses were performed within the R/Bioconductor
software (R Foundation for Statistical Computing, Vienna,
Austria). First, the quality of the microarrays was as-
sessed by diagnostic plots (eg, a red/green density plot
and an MA plot) and hierarchal clustering. The back-
ground was then corrected using a normexp  offset
method.49 Data were normalized within and between
samples using the Loess and Aquantile methods, re-
spectively. The LIMMA model was used to identify the
mRNAs, which were preferentially associated with Msi1.50
We used a conservative threshold of three-fold enrichment
and an adjusted P1  107. The microarray data were
deposited in the NCBI Gene Expression Omnibus under the
accession number GSE30904 (http://www.ncbi.nlm.nih.
gov/geo).
Quantitative RT-PCR
We performed RIP-PCR to validate the RIP-chip data.
Immunoprecipitated RNA was recovered and amplified
using the NuGEN Ovation RNA Amplification kit (NuGEN
Technologies, San Carlos, CA). Complementary DNA
was synthesized using Applied Biosystems High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems,
Carlsbad, CA) using random priming. Quantitative PCR
was performed using the TaqMan Gene Expression Mas-
Musashi1 in Medulloblastoma 1765
AJP November 2012, Vol. 181, No. 5ter Mix (Applied Biosystems). All reactions were run on an
ABI 7500 Real Time PCR machine (Applied Biosystems).
The data were acquired using the ABI SDS software
package version 2.0.1 (Applied Biosystems) and ana-
lyzed using the 2-Ct method.
Polysome Profiling
HEK293T cells were transfected in a 100-mm cell culture
plate with an Msi1 expression construct and a green
fluorescent protein (GFP) expression construct as nega-
tive control. Translation was arrested by adding 100
g/mL of cycloheximide (Sigma-Aldrich) for 10 minutes
for 72 hours after transfection. Cells were lysed in plate
using a polysome lysis buffer (20 mmol/L Tris, pH 7.4,
250 mmol/L NaCl, 15 mmol/L MgCl2, 1 mmol/L dithiothre-
itol, 0.5% Triton X-100, 24 U/mL of Turbo DNase, and 100
g/mL of cycloheximide). After scraping, the cells were
triturated with a pipette. The lysate was incubated on ice
for 10 minutes, clarified via centrifugation for 10 minutes
at 11,592  g at 4°C, and then overlaid on a 10% to 50%
sucrose gradient in a buffer solution of 20 mmol/L Tris-
HCl, pH 7.5, 100 mmol/L NaCl, 5 mmol/L MgCl2, and 0.1
mg/mL of cycloheximide. After ultracentrifugation at
113,422  g at 4°C, 1-mL fractions were obtained on a
Brandel density gradient fractionation system. A254 was
measured during the entire fractionation process.
The monosomes and polysomes fractions were com-
bined in separate tubes. RNA was extracted using the
TRIzol reagent (Invitrogen) and resuspended in nu-
clease-free water (Ambion). Complementary DNA was
synthesized using Applied Biosystems High Capacity
cDNA Reverse Transcription Kit using random priming.
Quantitative PCR was performed as described. Polysome
association was calculated according to Peng et al,51
with high polysome association taken as a proxy of high
translation activity. In brief, the mRNA levels in the poly-
some and monosome fractions were calculated. Then,
the percentage of mRNA in the polysome fraction relative
to the total (polysome plus monosome fractions) was
determined. The percentage values were normalized to
the control GFP expression (setting the GFP value at 1).
Computational Data Analysis
To identify transcripts with similar expression asMSI1, we
computed the Pearson correlation coefficients of the Msi1
expression profile across a medulloblastoma microarray
study52 to those of all other genes in the data set. Genes
displaying strong positive correlation or anticorrelation
(|R|  0.5) with Msi1’s profile were used in subsequent
analysis.
To determine biological processes strongly associated
with Msi1 and to explore the relationships of putative Msi1
targets, we analyzed all data sets with Pathway Studio 9
(Ariadne Genomics Inc., Rockville, MD), an automated
text-mining tool based on published literature from vari-
ous sources (eg, protein-protein interactions and gene
co-expression).Results
MSI1 Expression Is Elevated in
Medulloblastoma and Is an Indicator of Poor
Prognosis
We analyzed MSI1 expression in medulloblastoma ver-
sus normal cerebellar tissue using a large cohort of
medulloblastoma samples (n  103).52 Overall, MSI1 ex-
pression levels in medulloblastoma are significantly
higher than in adult cerebellum, where expression is re-
stricted to the external granular cell layer (P  0.001)
(Figure 1A).11 Fetal cerebellar tissue also presents high
MSI1 expression, which is consistent with the role of Msi1
during neurogenesis in the developing brain.11 We also
found that MSI1 expression is significantly elevated in
medulloblastoma molecular subgroups 3 and 4, which
are associated with a poor and intermediate prognosis,
respectively, compared with the less severe WNT and
SHH subgroups as defined by Taylor et al53 using the
Toronto series (n  103, P 0.001) (Figure 1B) and
Heidelberg series (see Supplemental Figure S2 at http://
ajp.amjpathol.org) (n  64) of gene expression cohort
data.52,54,55
Furthermore, Msi1 expression was evaluated by immu-
nohistochemistry in 259 tumor samples on two medullo-
blastoma tissue microarrays. Among these samples, 59
(23%) were immunonegative, whereas the remaining 200
tumors (77%) demonstrated strong and homogeneous
Msi1 expression (Figure 1C). Survival analysis by the
Kaplan-Meier estimate and log-rank test revealed a sig-
nificant association of Msi1 immunoreactivity with poor
overall survival (P0.0001) (Figure 1D) and progression-
free survival (P0.0001) (Figure 1E). We then delineated
Msi1 expression in a subgroup-specific manner. For in-
stance, we found that 98% of group 3 tumors have high
Msi1 expression, whereas this number is only 53% in the
case of WNT subgroup (see Supplemental Figure S3 at
http://ajp.amjpathol.org). Moreover, when we focused on
groups 3 and 4 tumors, we determined that high Msi1
expression denotes poor prognosis and overall survival
compared with the Msi1-negative tumors (see Supple-
mental Figure S4 at http://ajp.amjpathol.org). These find-
ings strongly support Msi1’s role in tumorigenesis of high-
risk medulloblastoma and, importantly, suggest its use as
a prognostic marker.
Msi1 Contributes to Medulloblastoma
Formation
We previously showed that Msi1 affects the viability of
Daoy cells grown as tumor spheroids and cell prolifera-
tion by cell colony formation assay.46 Building on these
studies, we examined the role of Msi1 in medulloblas-
toma growth in xenografts of Daoy cells (Figure 2A).
Fifteen days after cell implantation, tumors were treated
with multiple injections of either a control (scrambled) or
Msi1 siRNA. Tumor volume was measured at various time
points, and tumor weight (Figure 2B) was determined on
euthanasia. Tumors subjected to Msi1 siRNA treatment
of 12 m
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compared with the tumors injected with control siRNA
and nontreated controls (P  0.002) (Figure 2C). Tumors
treated with control siRNA had a slight increase com-
pared with the nontreated control, a similar effect that
was previously observed.30 Xenografts were immunohis-
tochemically stained for Msi1 and Notch1 to corroborate
the effects of the siRNA knockdown (Figure 2D). A de-
crease in Notch expression on Msi1 knockdown was
expected based on the fact that Msi1 represses Numb, a
Notch inhibitor.
Genome-Wide Analyses Suggest that Msi1
Affects Tumorigenesis in Multiple Ways
Previous data from our laboratory indicated that through
its binding to multiple RNA species, Msi1 controls a com-
plex network of genes from multiple biological pro-
cesses.21 To investigate the impact of Msi1 in medullo-
blastoma, we conducted two genomic analyses. We
started by mapping genes highly correlated (positively
and negatively) with MSI1 expression by exploring the
microarray data from our medulloblastoma cohort (n 
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mRNAs identified via RIP-chip in U251 glioblastoma
cells (Vo et al, unpublished data). The presence of com-
mon targets across cell lines corroborates the efficiency
of our approach to identify Msi1 target mRNAs. Data were
validated by RIP-PCR (see Supplemental Figure S6 at
http://ajp.amjpathol.org).
We examined the 3= UTRs of the 52 identified putative
Msi1 targets for evidence of the binding sites recently
described by the Ohyama et al.57 For each target 3= UTR,
we counted the number of occurrences of the GUAG and
UAG oligomers and normalized each count by the length
of the UTR. We did the same for nontarget 3= UTRs. On
average, GUAG occurs 30% more frequently and UAG
50% more frequently in the target 3= UTRs when com-
pared with nontarget 3= UTRs (P 1.6 106 and 9.2
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Figure 2. Msi1 silencing caused tumor regression of medulloblastoma cells
grown as xenografts. Daoy medulloblastoma cells were implanted into the
flank of nude mice and subjected to various treatments: nontreated control,
scrambled siRNA injection, and Msi1 siRNA injection. Tumor size was mea-
sured at different time points, and tumor weight was calculated at the end of
the experiment. A: Representative gross images of tumors from each of the
treatment after extirpation. Scale bar  1 cm. B: Graph representing the
measurement of the tumor volume, in cubic millimeters, throughout
the experiment. The data are shown as mean  SE of mean (SEM) (n  5).
C: Tumor weights, in grams, at the final point of the experiment. Treatment
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Representative images of each slide are shown. Notch1 expression is de-
creased when tumors are treated with Msi1 siRNA; thus, Notch1 is used as a
readout for Notch signaling activity. Original magnification, 40.1020, respectively; Wilcoxon rank-sum test). Further-more, we examined the most enriched targets in the
RIP-chip data and observed the same distinct pattern
of AUG and GUAG oligomers separated by a variable
length linker region as was recently reported57 (Figure
3). These results lend further support both for the pu-
tative Msi1 binding motif and for the accuracy of the
identified targets.
Pathway Studio 9 determined significant correlation be-
tween identified Msi1 associated mRNAs and cancer rele-
vant processes [apoptosis (	44%), cell cycle (	24%), cell
differentiation (	40%), cell proliferation (	46%), cell sur-
vival (	36%), and DNA repair (	7%)]. All observed values
showed enrichment over total transcriptome (P  0.1–
0.001) (Figure 4 and Table 1).
To have a broader view of Msi1’s impact on medullo-
blastoma and to identify the main mediators of its func-
tion, we conducted an in silico network analysis of the
functional relationships between Msi1’s associated
mRNAs and correlated genes. Links between genes are
drawn by Pathway Studio based on regulation, functional,
and biological associations extracted from the literature
(Figure 5; see also Supplemental Table S3 at http://
ajp.amjpathol.org).
Msi1 Potentially Regulates Translation of
Target mRNAs
To determine changes in translation efficiency as a con-
sequence of Msi1 binding, we performed a polysome
association experiment. HEK293T cells were transfected
with either a GFP (negative control) or a Msi1 expression
construct.42,43 Cellular lysate was prepared and the poly-
some fraction (which contains highly translated mRNAs)
and monosome fraction (which contains poorly translated
mRNAs) were separated by ultracentrifugation in a sucrose
density gradient. Quantitative RT-PCR was then used to
measure the impact of Msi1 transgenic expression on poly-
some association of a group mRNAs in experimental
versus control samples (Figure 6). We focused on a set of
mRNAs that had been identified as preferentially associ-
ated with Msi1 both in Daoy and HEK293T cells,21 thus
representing highly likely Msi1 targets. We observed that
AASDHPPT, ATP6AP2, ATP6V1G1, and KIAA0101 have
decreased polysome association on Msi1 expression,
suggesting translational repression by Msi1 (as has been
observed for other genes5,13,14).
Discussion
In this report, we determined the relevance of Msi1 to
medulloblastoma, the most common malignant brain tu-
mor in children.58 The design of more efficient therapies
requires a more elaborate study of this cell population,
including the mapping and characterization of key regu-
lators such as Msi1 that maintain the balance between
self-renewal and differentiation under normal circum-
stances but can trigger or contribute to tumor formation
when aberrantly expressed. We have previously deter-
mined that Msi1 expression is elevated in Daoy medullo-
blastoma cells grown as spheroids, which are enriched
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Msi1 in these cells markedly affected their proliferation
and growth.46 Similar results were obtained with breast
cancer cells.29
Our data suggest that Msi1 is a marker of poor prog-
nosis of medulloblastoma because patients displaying
tumors with high Msi1 expression had a worse overall
survival and progression-free survival than patients
with tumors that had lower Msi1 expression. In agree-
ment with this observation, we demonstrated that Msi1
silencing in tumor xenografts caused an impact on tumor
growth. Therefore, we conclude that Msi1 is not only a
marker of poor prognosis in medulloblastoma but also is
required for tumorigenesis.
Recent analyses of a large cohort of medulloblastoma
gene expression data have defined four molecular sub-
groups of medulloblastoma with different prognostic out-
comes (SHH, WNT, group 3, and group 4).53 By exam-
ining the expression of MSI1 in this data set, we
determined that high MSI1 expression is prevalent in
subgroups 3 and 4, being particularly high in group 4.
Groups 3 and 4 display a clear class separation from the
Table 1. Genes Identified by RIP-chip are Associated with Cance
Gene name Apoptosis Cell cycle Cell differentia
RAC1 x x x
CTGF x x x
PTGS1 (COX1) x x x
SDCBP x x
HERPUD1* x x
SRSF3 x x
ARL6IP1* x x x
ATP6AP2* x x
CD164* x x x
CDK2AP1 x x x
PDCD6 x x
PKNOX1* x x x
VAMP7 x x
BTG3* x x x
DNAJB9 x x x
GDE1 x x
KIAA0101* x x
VAPA x x
FSTL1 x x
HSBP1* x x x
LAPTM4B x
MAP1LC3B x
UBE2E3* x x
AASDHPPT*
SPOCK1
TSPAN3*
ZFAND5 x
Pathway Studio 9 was used to map mRNAs preferentially associated
*Genes previously identified in a study with HEK293T cells.21
x, biological processes associated with each gene.
chr12 92419367  92419416  MRPL42   ACUUU
chr3  160029969 160030018 MFSD1    UCUGA
chr9  116400678 116400727 ATP6V1G1 CAAAU
chr8  59657006  59657055  SDCBP    CAUCU
chr2  181636007 181636056 UBE2E3   CAAAAFigure 3. Identification of putative Msi1 binding sites. Highlighted in bold are the
the RNA recognition motif 1 (RRM1) of Msi1, and UAG corresponds to the putativeother two subgroups of medulloblastoma, WNT and SHH.
This stratification of MSI1 expression correlates with pa-
tients in groups 3 and 4 having a poor and intermediate
prognosis, respectively, compared with the WNT and
SHH subgroups, which have relatively good prognosis.53
Msi1 seems to influence tumorigenesis in multiple
ways as suggested by our RIP-chip studies. We focus the
discussion on the major nodes identified by analysis of a
functional network. We discuss selected genes whose
degree in the network is higher than the median degree.
Among the RIP-chip identified targets, we highlight
RAC1, CTGF, and SDCBP. Rac1 is a member of the Ras
superfamily of GTP-binding proteins that has many cel-
lular roles, such as regulating gene expression, cell pro-
liferation, cytoskeleton reorganization, and metastasis.59
Previous studies observed abundant expression and ac-
tivity of Rac1 in medulloblastoma.60 Furthermore, silenc-
ing of Rac1 using RNA interference in Daoy, UW-228,
and OWS-76 cells leads to a reduced invasiveness.61 In
many cancers, CTGF functions in biological processes,
such as cell proliferation, migration, adhesion, extracel-
lular matrix formation, and angiogenesis.62 CTGF over-
ed Processes
Cell proliferation Cell survival DNA repair Total no.
x x x 6
x x 5
x x 5
x x 4
x x 4
x x 4
x x 5
x x 4
x x 5
x x 5
x x 4
x x 5
x 3
x 4
3
x x 4
x x 4
x x 4
x 3
x x 5
x x 3
x 2
x 3
x 1
x 1
x 1
1
i1 to biological processes.
GUGCCAAAGCCAUACAUAUUCAGUAGAACAUCAAUAAAU
ACAAUAGCUUGCGCUCUACUCUGUAGUUAUGUGGAUUGC
GAAAACAGCAAGCAACUAGUCUGUAGGUUGUCUUUUCUC
UUGUUCAGAUUUCAAAAUAGUUGUAGCCUUAUCCUGGUU
AUGCUAUCAAGAGUAGAACUUUGUAGCUGUAGAUUAGUUr-Relat
tion
with MsUCCAUA
UCACGA
GUUUUG
GAUACC
AGGUAAputative binding sites for Msi1. GUAG is the putative binding sequence for
binding site for Msi1 RRM2.
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AJP November 2012, Vol. 181, No. 5expression is found in many malignant tumors, such as
melanoma, prostate cancer, pancreatic cancer, esopha-
geal carcinoma, lymphoblastic leukemia, gastric cancer,
and gliomas.63–69 Enhanced CTGF expression provides
the cell with the ability to invade and grow in an anchor-
age-independent manner.62 SDCBP, or syntenin, is an
important molecule in connecting syndecan signaling to
the cytoskeleton through the binding of its PDZ motif to
syndecan proteoglycans.70 This interaction allows can-
cer cells to acquire the capability to migrate and invade;
in particular, this capability is garnered through the acti-
vation of c-Src, focal adhesion kinase, MAPK pathway,
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Figure 4. Msi1 putative targets are enriched for cancer-related process. We
used Pathway Studio 9 to analyze the biological processes connected with
Msi1-associated mRNAs. The graph shows the percentage of genes associ-
ated with each biological process in the Msi1 subset (gray) and in total
transcriptome (black). RIP-chip analysis of Msi1 results in an overall enrich-
ment of mRNAs related to apoptosis, cell cycle, cell differentiation, cell
proliferation, cell survival, and DNA repair versus the percentage of mRNAs
that resides in whole transcriptome that are connected to cancer-related
biological processes. Fisher’s exact test was used to calculate P values.and NF-B by syntenin.71–75 In addition to its Msi1 inter-
action observed by RIP-chip analysis, SDCBP also cor-
relates negatively with MSI1 gene expression (P 
0.0002).
Three major nodes come from the analysis of expres-
sion correlation: SRC, PRL, and SHC1. SRC (c-Src) is one
of the first proto-oncogenes discovered and provided a
launching point for the study of the molecular basis of
cancer.76 c-Src is one of the members of the SRC family
of kinases and is implicated in the development and
progression of various human cancers. Elevated expres-
sion of c-Src is observed in a number of different cancer
types.77 c-Src has a wide range of different kinase sub-
strates, which includes proteins such as RasGAP SH3-
Figure 5. Network analysis of Msi1. Blue ovals
indicate Msi1 RIP-chip targets in Daoy cells (this
study), and red ovals are genes whose expres-
sion is correlated to Msi1 (Pearson’s R  0.5).
Links between nodes denote a functional re-
lationship between the two genes as reported
by literature, co-expression analysis, regula-
tion, and protein-protein interaction analysis.
The edges are directed to denote regulator-target
relationships as determined by local connectivity.
The figure illustrates the high connectivity of genes
controlled by Msi1 expression.
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Figure 6. Msi1 affects ribosomal profile of associated mRNAs. 293T cells
were transfected with expression constructs for Msi1 (pEF1-Msi1) or GFP
(pEF1-GFP). After 72 hours of transfection, translation was arrested with
cycloheximide, and cell lysates were prepared and analyzed on a sucrose
density gradient. The polysome association for each selected mRNA was
calculated according to Peng et al51 and compared between Msi1 and GFP.
GAPDH and ACTB, which were not identified to be associated with Msi1,
were used as a negative control. Transgenic expression of Msi1 repressed
polysome association of four of the five analyzed target mRNAs without
affecting GAPDH and ACTB. Data were analyzed with Student’s t-test and are
presented as mean  SEM. Experiments were performed in triplicate. *P 
0.01, ***P  0.001.
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gion 1, and heteronuclear ribonucleoprotein A2/B1.78
The cellular effects of c-Src are evident and widespread.
c-Src expression can transform normal fibroblast so that
the cell is now able to proliferate faster, lose density-
dependent growth inhibition, and form tumors in in vivo
xenograft models. Like many other tumor types, c-Src is
overexpressed in medulloblastoma.79 Because c-Src ex-
pression is so potent and a potential therapeutic target,
inhibition of c-Src kinase activity with novel inhibitors,
such as pyrazolo-[3,4-day]-pyrimidine derivatives, can
reduce the growth rate of medulloblastoma cells by ar-
resting cell cycle progression at the G2/M transition and
induce apoptosis.80 PRL is a luteotropic hormone protein
whose best characterized effect is the stimulation of
mammary glands to produce milk. In the maternal central
nervous system, PRL can stimulate the proliferation of
oligodendrocyte precursor cells and enhance remyelina-
tion.81 In cancers such as mammary, prostate, colorectal,
and glioblastoma, PRL may have a role in the induction
and progression of these cancers.82 In medulloblastoma,
PRL expression is high and may serve as a potential target
for therapy.83 SHC1 (also known as SHCA) is a signal trans-
duction adaptor protein that relays extracellular signals
downstream of receptor tyrosine kinases. SHC1 has a wide
range of functions through its promotion of proliferation,
angiogenesis, migration, and invasion.84–87 In medullo-
blastoma, SHC1 expression is elevated in metastatic
medulloblastoma samples compared with nonmetastatic
samples, suggesting a potential role of SHC1 in mediat-
ing metastasis of medulloblastoma.88
In summary, our study establishes a functional role of
Msi1 in medulloblastoma through posttranscriptional
control of a subset of cancer-related mRNAs. Studies
such as this underline the importance of RBPs and post-
transcriptional gene regulation in the molecular patho-
genesis of cancer. We believe that further studies will
likely demonstrate that more RBPs are directly involved in
tumorigenesis. In fact, in a previous in silico study from
our laboratory, we identified 53 RBPs aberrantly ex-
pressed in multiple tumor types.89 Further systematic
studies are required to understand the role of posttran-
scriptional gene regulation in tumorigenesis and its inter-
action with known cancer signaling pathways and to
identify novel therapeutic targets for cancer treatment.
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